{"id":75809,"date":"2025-05-05T06:47:09","date_gmt":"2025-05-05T06:47:09","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/75809\/"},"modified":"2025-05-05T06:47:09","modified_gmt":"2025-05-05T06:47:09","slug":"rare-disease-genetic-testing-market-projected-to-reach-usd","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/75809\/","title":{"rendered":"Rare Disease Genetic Testing Market Projected to Reach USD"},"content":{"rendered":"

\"Rare<\/a><\/p>\n

Rare Disease Genetic Testing Market<\/p>\n

In 2024, the rare disease genetic testing market was valued at USD 1,106.88 million. Over the forecast period, it is anticipated to grow from USD 1,242.80 million in 2025 to USD 3,790.38 million by 2034 at a CAGR of 13.2%.<\/p>\n

Market Details :

\nRare disease genetic testing involves analyzing an individual’s genetic material (DNA) to identify specific mutations or changes associated with a rare genetic disorder. This can help confirm or rule out a suspected diagnosis, provide insights into the underlying cause of a disease, and inform treatment and management strategies. The primary goal of rare disease genetic testing is to pinpoint genetic variations that cause a rare disease or condition. Genetic testing can involve analyzing specific genes known to be linked to a particular rare disease, or it can involve sequencing an individual’s entire genome to identify a wider range of potential genetic changes. Identifying the specific genetic mutation by testing can shed light on the underlying mechanism of the disease, potentially leading to better understanding and management strategies.<\/p>\n

Download Free Sample PDF Copy of the Report:

\nhttps:\/\/www.polarismarketresearch.com\/industry-analysis\/rare-disease-genetic-testing-market\/request-for-sample <\/p>\n

Growth Drivers:

\n\u2022\tThe growth of the market is being fueled by advancing technology and the growing occurrence of chronic diseases. <\/p>\n

\u2022\tThe creation of tailored testing kits aimed at specific therapies is driving growth in the genetic testing market for rare diseases. <\/p>\n

\u2022\tThe growing focus on early disease identification and prevention drives the expansion of the rare disease genetic testing market. <\/p>\n

\u2022\tThe market is being fueled by the rising awareness about the importance of genetic testing in early cancer identification and risk evaluation. <\/p>\n

Competitive Landscape:

\nThe rare disease genetic testing market presents a competitive environment, comprising both established firms and new entrants seeking to enhance their market share. Some of the major players in the market are:

\n\u2022\t3billion, Inc.

\n\u2022\tAmbry Genetics

\n\u2022\tBaylor Genetics

\n\u2022\tBlueprint Genetics (Quest Diagnostics)

\n\u2022\tCentogene N.V.

\n\u2022\tEurofins Scientific

\n\u2022\tGeneDx, LLC

\n\u2022\tGenomenon

\n\u2022\tInvitae Corporation

\n\u2022\tRevvity<\/p>\n

Request for a Discount on this Report Before Purchase:

\nhttps:\/\/www.polarismarketresearch.com\/industry-analysis\/rare-disease-genetic-testing-market\/request-for-discount-pricing <\/p>\n

Rare Disease Genetic Testing Industry Developments

\n\u2022\tJanuary 2024: Invitae formed a partnership with BridgeBio Pharma to advance genetics-based drug discovery for rare diseases, combining their expertise to drive innovation in the field.<\/p>\n

\u2022\tApril 2023: Centogene N.V. introduced the new CentoGenome, an advanced whole genome sequencing test that provides comprehensive diagnostic insights for rare and neurodegenerative diseases.<\/p>\n

\u2022\tOctober 2022: Ambry Genetics launched a new reproductive health program, powered by its CARE ProgramTM (Comprehensive Assessment Risk and Education), a digital platform designed to enhance the patient and provider experience by offering easier access to genetic education, testing, reporting, and counseling.<\/p>\n

Region-Wise Overview:

\n\u2022\tNorth America represented the largest market share in 2024, due to the growing need for personalized genetic testing services and the increasing incidence of chronic and genetic diseases. <\/p>\n

\u2022\tEurope held the second largest share of the global market, propelled by an increase in chronic diseases and an elderly population. <\/p>\n

Click here to Access the Full Report:

\nhttps:\/\/www.polarismarketresearch.com\/industry-analysis\/rare-disease-genetic-testing-market <\/p>\n

Segmental Analysis:

\n\u2022\tThe rare disease genetic testing market is segmented primarily based on specialty, technology, disease type, end use, and region.<\/p>\n

\u2022\tThe next-generation sequencing (NGS) segment, based on technology, dominated the market share in 2024, because of its extensive usage in diagnosing a range of conditions, such as cardiovascular issues, neurological ailments, pediatric disorders, and mental health disorders. <\/p>\n

Buy Now:

\nhttps:\/\/www.polarismarketresearch.com\/buy\/724\/0 <\/p>\n

By Technology Outlook (Revenue, USD Million, 2020-2034)

\n\u2022\tNext-Generation Sequencing

\n\u2022\tArray Technology

\n\u2022\tPCR-Based Testing

\n\u2022\tFISH

\n\u2022\tSanger Sequencing

\n\u2022\tKaryotyping<\/p>\n

By Speciality Outlook (Revenue, USD Million, 2020-2034)

\n\u2022\tMolecular Genetic Tests

\n\u2022\tChromosomal Genetic Tests

\n\u2022\tBiochemical Genetic Tests<\/p>\n

By Disease Type Outlook (Revenue, USD Million, 2020-2034)

\n\u2022\tNeurological Disease

\n\u2022\tImmunological Disorders

\n\u2022\tHematology Diseases

\n\u2022\tEndocrine & Metabolism Diseases

\n\u2022\tCancer

\n\u2022\tMusculoskeletal Disorders

\n\u2022\tCardiovascular Disorders

\n\u2022\tDermatology Disease

\n\u2022\tOthers<\/p>\n

By End Use Outlook (Revenue, USD Million, 2020-2034)

\n\u2022\tResearch Laboratories & CROs

\n\u2022\tHospitals & Clinics

\n\u2022\tDiagnostic Laboratories<\/p>\n

Browse More Research Reports:

\nFoley Catheter Market:

\nhttps:\/\/www.polarismarketresearch.com\/industry-analysis\/foley-catheter-market <\/p>\n

Canadian Oilfield Chemicals Market:

\nhttps:\/\/www.polarismarketresearch.com\/industry-analysis\/canadian-oilfield-chemicals-market <\/p>\n

OEM insulation market:

\nhttps:\/\/www.polarismarketresearch.com\/industry-analysis\/oem-insulation-market <\/p>\n

endoscopic submucosal dissection market:

\nhttps:\/\/www.polarismarketresearch.com\/industry-analysis\/endoscopic-submucosal-dissection-market <\/p>\n

Cloud Infrastructure Entitlement Management Market:

\nhttps:\/\/www.polarismarketresearch.com\/industry-analysis\/cloud-infrastructure-entitlement-management-market<\/p>\n

Contact:

\nLikhil G

\n8 The Green Ste 19824,

\nDover, DE 19901,

\nUnited States

\nPhone: +1-929 297-9727

\nEmail: sales@polarismarketresearch.com

\nWeb: https:\/\/www.polarismarketresearch.com

\nFollow Us: LinkedIn | Twitter<\/p>\n

About Polaris Market Research & Consulting, Inc:

\nPolaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.<\/p>\n

This release was published on openPR.
\n <\/p>\n","protected":false},"excerpt":{"rendered":"Rare Disease Genetic Testing Market In 2024, the rare disease genetic testing market was valued at USD 1,106.88…\n","protected":false},"author":2,"featured_media":75810,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3846],"tags":[3369,267,3368,3364,3362,3367,3371,3370,3372,3361,3365,3363,3366,70,16,15],"class_list":{"0":"post-75809","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-advertising","9":"tag-genetics","10":"tag-marketing","11":"tag-media-release","12":"tag-news-release","13":"tag-pr","14":"tag-pr-marketing","15":"tag-pr-service","16":"tag-pr-strategy","17":"tag-presses-release","18":"tag-pressreleases","19":"tag-public-relations","20":"tag-publicity","21":"tag-science","22":"tag-uk","23":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114453889074830251","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/75809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=75809"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/75809\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/75810"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=75809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=75809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=75809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}